Twist Bioscience Corp TWST
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment
-
Twist Biosciences Shares Rise on Deal With Eli Lilly's TuneLab
-
Twist Bioscience Joins Lilly TuneLab to Advance Antibody Drug Discovery
-
Twist Bioscience to Present at Baird 2026 Global Healthcare Conference
-
AI in Drug Discovery Market Projected to Reach $8.52 Billion By 2030
-
Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock
-
Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stock
-
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Trading Information
- Previous Close Price
- $188.05
- Day Range
- $183.39–198.10
- 52-Week Range
- $23.30–200.31
- Bid/Ask
- $189.25 / $190.50
- Shares Outstanding
- 66.30M
- Market Cap
- $12.51B
- Volume/Avg
- 2M / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 26.59
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- < 0.01%
Company Profile
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company’s proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 979
- Website
- https://www.twistbioscience.com
Valuation
|
Metric
|
TWST
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 26.44 |
Price/Sales | 26.59 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
TWST
|
|---|---|
Quick Ratio | 2.12 |
Current Ratio | 2.67 |
Interest Coverage | — |
Quick Ratio
TWST
Profitability
|
Metric
|
TWST
|
|---|---|
Return on Assets (Normalized) | −12.00% |
Return on Equity (Normalized) | −17.01% |
Return on Invested Capital (Normalized) | −15.43% |
Return on Assets
TWST
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|rLj@%FZ | LOCK|VRQM | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|@?&GY>! | LOCK|rYFF< | $76B | |||
| Moderna Inc
MRNA
| LOCK|$!TvxF | LOCK|j> | $75B | |||
| argenx SE ADR
ARGX
| LOCK|&&PWqVY | LOCK|%H | $60B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|r<lf>n | LOCK|%cl | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|qPZ#M!% | LOCK|W!znm | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|Jn#<&#xg | LOCK|X>dP | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|Kn$j%^ | LOCK|sh | $24B | |||
| Incyte Corp
INCY
| LOCK|Dfk^t> | LOCK|V%% | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|R^k$T<> | LOCK|&c | $15B |
United States